Tsagkouli Sofia, Kyriakoulis Ioannis G, Kyriakoulis Konstantinos G, Fyta Eleni, Syrigos Alexandros, Bakakos Petros, Charpidou Adrianni, Kotteas Elias
Third Department of Medicine, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
First Department of Chest Medicine, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2022 Jun 8;14(12):2825. doi: 10.3390/cancers14122825.
Mesothelioma, a malignant neoplasm of mesothelial cells, has overall poor prognosis. Cell adhesion molecules (CAMs) are proteins that contribute to the immune response. In this study the clinical utility and prognostic significance of serum and pleural fluid soluble CAM (sCAM) levels were assessed in patients with mesothelioma. Mesothelioma patients were retrospectively recruited (2016-2020). Clinical characteristics, serum and pleural sCAM levels (sE-cadherin, sE-selectin, intercellular adhesion molecule 1 (sICAM-1) and vascular cell adhesion molecule 1 (sVCAM-1)) and histopathological characteristics were gathered. A total of 51 healthy controls were also recruited for a secondary cross-sectional analysis. 92 mesothelioma patients were analyzed (mean age 64.5 years, 87% males, performance status 0-2). Patients with increased pleural sE-cadherin had higher risk for disease progression (adjusted HR 1.11 (1.02, 1.20), = 0.013). Serum and pleural sE-selectin were decreased in patients with high-grade mesothelioma. Patients with increased serum or pleural sE-selectin levels had lower risk for death (adjusted HR 0.88 (0.81, 0.96), = 0.003; 0.90 (0.82, 0.99), = 0.039, respectively). Serum sE-cadherin, sE-selectin and sICAM-1 levels were significantly increased in mesothelioma patients compared to healthy controls. Further studies are needed to indicate the clinical utility of serum and pleural sCAMs in mesothelioma patients.
间皮瘤是一种间皮细胞的恶性肿瘤，总体预后较差。细胞黏附分子（CAMs）是有助于免疫反应的蛋白质。在本研究中，评估了间皮瘤患者血清和胸水淀粉溶性CAM（sCAM）水平的临床效用和预后意义。对间皮瘤患者进行回顾性招募（2016 - 2020年）。收集临床特征、血清和胸水sCAM水平（可溶性E - 钙黏蛋白、可溶性E - 选择素、细胞间黏附分子1（sICAM - 1）和血管细胞黏附分子1（sVCAM - 1））以及组织病理学特征。还招募了51名健康对照进行二次横断面分析。对92例间皮瘤患者进行了分析（平均年龄64.5岁，87%为男性，体能状态0 - 2）。胸水可溶性E - 钙黏蛋白升高的患者疾病进展风险更高（校正后风险比1.11（1.02，1.20），P = 0.013）。高级别间皮瘤患者血清和胸水可溶性E - 选择素降低。血清或胸水可溶性E - 选择素水平升高的患者死亡风险较低（校正后风险比分别为0.88（0.81，0.96），P = 0.003；0.90（0.82，0.99），P = 0.039）。与健康对照相比，间皮瘤患者血清可溶性E - 钙黏蛋白、可溶性E - 选择素和可溶性ICAM - 1水平显著升高。需要进一步研究以表明血清和胸水sCAMs在间皮瘤患者中的临床效用。
